BLCO

Bausch + Lomb Corp

BLCO, USA

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

https://www.bausch.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BLCO
stock
BLCO

Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year The Globe and Mail

Read more →
BLCO
stock
BLCO

1 Profitable Stock to Keep an Eye On and 2 We Question FinancialContent

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$16.6333

Analyst Picks

Strong Buy

3

Buy

3

Hold

8

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.94

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-0.44 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.20 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

5.04 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.14

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 9.02% of the total shares of Bausch + Lomb Corp

1.

ICAHN CARL C

(0.9891%)

since

2025/06/30

2.

Deutsche Bank AG

(0.9637%)

since

2025/06/30

3.

Alberta Investment Management Corp

(0.923%)

since

2025/06/30

4.

D. E. Shaw & Co LP

(0.7367%)

since

2025/06/30

5.

Goldentree Asset Management LP

(0.73%)

since

2025/06/30

6.

Oaktree Capital Management LLC

(0.7125%)

since

2025/06/30

7.

Glenview Capital Management LLC

(0.4391%)

since

2025/06/30

8.

Whitebox Advisors, LLC

(0.365%)

since

2025/06/30

9.

Nomura Holdings Inc

(0.355%)

since

2025/06/30

10.

T. Rowe Price Associates, Inc.

(0.353%)

since

2025/06/30

11.

River Road Asset Management, LLC

(0.3476%)

since

2025/06/30

12.

Arrowstreet Capital Limited Partnership

(0.3141%)

since

2025/06/30

13.

Clearline Capital LP

(0.2582%)

since

2025/06/30

14.

Canada Pension Plan Investment Board

(0.2407%)

since

2025/06/30

15.

Clark Estates Inc

(0.2402%)

since

2025/06/30

16.

UBS Group AG

(0.2339%)

since

2025/06/30

17.

Compass Rose Asset Management LP

(0.2317%)

since

2025/06/30

18.

FMR Inc

(0.2181%)

since

2025/06/30

19.

Allianz Asset Management AG

(0.2173%)

since

2025/06/30

20.

TANG CAPITAL MANAGEMENT LLC

(0.1554%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(2.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(3.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

Bausch + Lomb Corp (BLCO) Stock Details & Analysis - Finnton | Finnton